243 related articles for article (PubMed ID: 23629633)
41. Cardiac function in women receiving dual anti-Her2 antibodies (trastuzumab and pertuzumab) combined with chemotherapy for breast cancer.
Zekri J; Rasool H; Rizvi SAJ; Eldeeb H; Al-Gahmi A; Farag K; Rasmy A
Womens Health (Lond); 2023; 19():17455057231166837. PubMed ID: 37148305
[TBL] [Abstract][Full Text] [Related]
42. First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial.
Untch M; Muscholl M; Tjulandin S; Jonat W; Meerpohl HG; Lichinitser M; Manikhas AG; Coumbos A; Kreienberg R; du Bois A; Harbeck N; Jackisch C; Müller V; Pauschinger M; Thomssen C; Lehle M; Catalani O; Lück HJ
J Clin Oncol; 2010 Mar; 28(9):1473-80. PubMed ID: 20177030
[TBL] [Abstract][Full Text] [Related]
43. Dual HER2 blockade: preclinical and clinical data.
Patel TA; Dave B; Rodriguez AA; Chang JC; Perez EA; Colon-Otero G
Breast Cancer Res; 2014 Aug; 16(4):419. PubMed ID: 25928889
[TBL] [Abstract][Full Text] [Related]
44. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
45. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
46. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
Guarneri V; Frassoldati A; Bottini A; Cagossi K; Bisagni G; Sarti S; Ravaioli A; Cavanna L; Giardina G; Musolino A; Untch M; Orlando L; Artioli F; Boni C; Generali DG; Serra P; Bagnalasta M; Marini L; Piacentini F; D'Amico R; Conte P
J Clin Oncol; 2012 Jun; 30(16):1989-95. PubMed ID: 22493419
[TBL] [Abstract][Full Text] [Related]
47. The cardiac safety of trastuzumab in the treatment of breast cancer.
Chien AJ; Rugo HS
Expert Opin Drug Saf; 2010 Mar; 9(2):335-46. PubMed ID: 20175700
[TBL] [Abstract][Full Text] [Related]
48. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.
Cortés J; Fumoleau P; Bianchi GV; Petrella TM; Gelmon K; Pivot X; Verma S; Albanell J; Conte P; Lluch A; Salvagni S; Servent V; Gianni L; Scaltriti M; Ross GA; Dixon J; Szado T; Baselga J
J Clin Oncol; 2012 May; 30(14):1594-600. PubMed ID: 22393084
[TBL] [Abstract][Full Text] [Related]
49. Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials.
Du F; Yuan P; Zhu W; Wang J; Ma F; Fan Y; Xu B
Med Oncol; 2014 Dec; 31(12):340. PubMed ID: 25416049
[TBL] [Abstract][Full Text] [Related]
50. Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
Saini KS; Azim HA; Metzger-Filho O; Loi S; Sotiriou C; de Azambuja E; Piccart M
Breast; 2011 Oct; 20 Suppl 3():S20-7. PubMed ID: 22015288
[TBL] [Abstract][Full Text] [Related]
51. Anthracycline and trastuzumab in breast cancer treatment.
Untch M; Himsl I; Kahlert S; Lueck HJ; Eidtmann H; Du Bois A; Meerpohl HG; Thomssen C; Harbeck N; Jackisch C; Kreienberg R; Emons G; Wallwiener D; Wiese W; Schaller G; Kuhn W; Muscholl M; Pauschinger M; Langer B
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 14):59-64. PubMed ID: 15685838
[TBL] [Abstract][Full Text] [Related]
52. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis.
Valachis A; Mauri D; Polyzos NP; Chlouverakis G; Mavroudis D; Georgoulias V
Breast; 2011 Dec; 20(6):485-90. PubMed ID: 21784637
[TBL] [Abstract][Full Text] [Related]
53. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
54. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
Phillips GD; Fields CT; Li G; Dowbenko D; Schaefer G; Miller K; Andre F; Burris HA; Albain KS; Harbeck N; Dieras V; Crivellari D; Fang L; Guardino E; Olsen SR; Crocker LM; Sliwkowski MX
Clin Cancer Res; 2014 Jan; 20(2):456-68. PubMed ID: 24097864
[TBL] [Abstract][Full Text] [Related]
55. Pertuzumab in HER2-positive breast cancer.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
[TBL] [Abstract][Full Text] [Related]
56. Cardiac toxicities of lapatinib in patients with breast cancer and other HER2-positive cancers: a meta-analysis.
Choi HD; Chang MJ
Breast Cancer Res Treat; 2017 Dec; 166(3):927-936. PubMed ID: 28825152
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis.
Leung HWC; Leung JH; Chan ALF
Expert Opin Drug Saf; 2018 Jan; 17(1):1-7. PubMed ID: 29108432
[TBL] [Abstract][Full Text] [Related]
58. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
Guarneri V; Barbieri E; Dieci MV; Piacentini F; Conte P
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S62-6. PubMed ID: 21129613
[TBL] [Abstract][Full Text] [Related]
59. Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer.
Sotelo MJ; García-Sáenz JA; Manso L; Moreno F; Ciruelos E; Callata HR; Mendiola C; Cabezas S; Ghanem I; Díaz-Rubio E
J Cancer Res Ther; 2014; 10(4):967-72. PubMed ID: 25579538
[TBL] [Abstract][Full Text] [Related]
60. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]